Pulmatrix, Inc. PULM
Pulmatrix, Inc. (Nasdaq: PULM) is a CNS/neurology/psychiatry drug developer. Its lead program, PUR3100 (inhaled dihydroergotamine, iSPERSE), is in Phase 1 for Acute migraine. Its next catalyst on record is PUR1900: Licensee Cipla expected to commence Phase 3 (ex-US; not sponsored by Pulmatrix) (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PUR1900 — Licensee Cipla expected to commence Phase 3 (ex-US; not sponsored by Pulmatrix) (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PUR1900 (inhaled itraconazole) | ABPA in asthma / cystic fibrosis (Company's Phase 2b stopped Jan 2024; ex-US development now by licensee Cipla, Phase 3 expected to commence in 2026; Pulmatrix holds 2% ex-US royalty and US rights it seeks to monetize) | small molecule | Phase 2 |
| PUR3100 | Acute migraine (Phase 1 complete 2022; Phase 2 IND cleared Sept 2023 but not started; all development on hold pending financing/partner) | small molecule | Phase 1 |
| PUR1800 | Acute exacerbations of COPD (Phase 1b complete; development on hold) | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.